Clinical Precision.
Institutional Capital.
Multiple Arbitrage.
A £100m clinician-led Private Equity fund executing a buy-and-build consolidation strategy in the UK lower-mid-market healthcare sector.
What is Ottimo Healthcare Fund I?
Ottimo Healthcare Fund I LP is a £100m clinician-led Private Equity fund targeting the highly fragmented UK lower-mid-market healthcare sector. Against the backdrop of historic NHS waiting lists (7.4m+ treatments) and surging private patient demand, the Fund executes a rigorous buy-and-build consolidation strategy. We acquire sub-scale independent clinics, diagnostic chains, and specialist hubs at attractive entry multiples, integrate them into a proprietary tech-enabled operating playbook, and drive rapid 30%+ EBITDA expansion. The goal: create a £30m+ EBITDA national platform positioned for a premium exit to Large-Cap PE or strategic acquirers in Year 5–7.
Founded by Dr. Raja Mohan, a doctor and London Business School graduate, Ottimo brings an operator's perspective to every acquisition. We understand healthcare businesses from the inside — the clinical workflows, the regulatory environment, the workforce pressures — because we've built and run them ourselves. The Fund bypasses the traditional "blind pool" setup phase with a proprietary seed asset: Chelmsford Health Centre (CHC), a fully operational, CQC-regulated multi-specialty hub in Essex. This de-risks Day 1 and provides immediate deployment of capital into a proven platform.
Our Pillars
Three principles that guide every acquisition decision
Buy & Build
We acquire sub-scale independent clinics at attractive entry multiples and consolidate them into a national platform. Our rigorous acquisition criteria target retiring founder-owned regional hospital groups, diagnostic chains, and specialist hubs in the £20m–£50m enterprise value range.
Operational Alpha
Acquired clinics are immediately integrated into our proprietary tech-enabled operating playbook: Medroid AI (clinical triage automation) and Rainbow Diagnostics (rapid in-house pathology). This drives rapid 30%+ EBITDA expansion by stripping out legacy overhead and accelerating patient throughput.
Multiple Arbitrage
The UK lower-mid-market exhibits a severe valuation gap. Single clinics trade at attractive entry multiples. Integrated, tech-enabled platforms generating £30m+ EBITDA command premium exit multiples. The Fund is engineered specifically to capture this multiple expansion over a 5-to-7-year hold period.
The Ottimo Operating Ecosystem
Proprietary vendor platforms that drive operational alpha across every acquisition
Medroid AI
Clinical Triage Automation
Proprietary AI-powered clinical triage platform that automates patient assessment, reduces administrative overhead and staffing costs, and accelerates patient throughput. Deployed across all Ottimo portfolio companies to drive operational efficiency and margin expansion.
Contracted at strict arm's-length market rates to ensure alignment with LP interests and regulatory compliance.
Rainbow Diagnostics
ISO-Accredited In-House Pathology
Proprietary ISO accredited pathology network that eliminates reliance on slow, expensive outsourced laboratory contracts. By routing diagnostic workflows through an internalised, tech-enabled platform, Rainbow delivers rapid test results, accelerates patient treatment cycles, and captures significant margin that is typically lost to third-party vendors.
Contracted at strict arm's-length market rates to ensure alignment with LP interests and regulatory compliance.
By deploying these proprietary platforms across every acquisition, Ottimo transforms single-digit margin clinics into 20%+ EBITDA compounding engines, creating sustainable operational alpha that drives both cash yield and long-term NAV growth.
Ready to Explore a Partnership?
Whether you're a healthcare business owner considering succession, an LP seeking exposure to UK healthcare consolidation, or a partner looking to build alongside clinical operators — we'd welcome the conversation.